Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $11.78 and last traded at $12.20, with a volume of 83218 shares. The stock had previously closed at $12.20.
Wall Street Analyst Weigh In
DAWN has been the subject of a number of recent analyst reports. TD Cowen raised Day One Biopharmaceuticals to a "strong-buy" rating in a research report on Monday, November 4th. Needham & Company LLC restated a "buy" rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Bank of America dropped their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday. Finally, HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals presently has an average rating of "Buy" and an average price target of $35.86.
Read Our Latest Research Report on DAWN
Day One Biopharmaceuticals Stock Performance
The stock's 50-day moving average price is $13.44 and its two-hundred day moving average price is $13.96. The stock has a market capitalization of $1.19 billion, a PE ratio of -11.46 and a beta of -1.46.
Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.58. The business had revenue of $93.76 million during the quarter, compared to analysts' expectations of $15.05 million. During the same quarter last year, the company posted ($0.54) EPS. On average, analysts predict that Day One Biopharmaceuticals, Inc. will post -0.88 earnings per share for the current fiscal year.
Insider Buying and Selling at Day One Biopharmaceuticals
In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $16.10, for a total value of $161,000.00. Following the completion of the transaction, the insider now directly owns 1,057,535 shares of the company's stock, valued at approximately $17,026,313.50. The trade was a 0.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders sold 51,745 shares of company stock worth $748,567. 8.40% of the stock is owned by insiders.
Hedge Funds Weigh In On Day One Biopharmaceuticals
Hedge funds have recently added to or reduced their stakes in the company. First Turn Management LLC purchased a new stake in Day One Biopharmaceuticals during the 3rd quarter valued at $13,204,000. GSA Capital Partners LLP purchased a new stake in shares of Day One Biopharmaceuticals during the third quarter valued at $825,000. Algert Global LLC increased its holdings in Day One Biopharmaceuticals by 248.8% in the 3rd quarter. Algert Global LLC now owns 71,487 shares of the company's stock worth $996,000 after buying an additional 50,990 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Day One Biopharmaceuticals by 14.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 507,448 shares of the company's stock worth $7,069,000 after buying an additional 64,700 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Day One Biopharmaceuticals by 10.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,432,697 shares of the company's stock valued at $19,961,000 after acquiring an additional 136,458 shares during the period. 87.95% of the stock is currently owned by hedge funds and other institutional investors.
About Day One Biopharmaceuticals
(
Get Free Report)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
See Also
Before you consider Day One Biopharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.
While Day One Biopharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
